Localized Prostate Cancer COE

AI-Derived Digital Pathology-Based Biomarker To Predict the Benefit of ADT in Localized Prostate Cancer – Dan Spratt

Details
In this conversation with Alicia Morgans, Daniel Spratt discusses artificial intelligence (AI)-derived digital pathology-based biomarker to predict the benefit of androgen deprivation therapy (ADT) in localized prostate cancer with validation in NRG/RTOG 9408. The current standard of care for men with intermediate- and high-risk localized prostate cancer treated with radiotherapy is the addition o...

Validation of Performance of the Decipher Biopsy Genomic Classifier in Intermediate-Risk Prostate Cancer: The Phase III Randomized Trial NRG Oncology/RTOG 0126 – Jeff Michalski

Details
Daniel Spratt and Jeff Michalski discuss the pivotal NRG Oncology RTOG 0126 trial from which Dr Michalski is the PI. This phase III randomized NRG/RTOG 0126 trial provides the first validation of the Decipher biopsy genomic classifier in intermediate-risk prostate cancer. Dr. Spratt provides the background on the rationale for the NRG/RTOG 0126 and the results from the RTOG 0126 trial. They discus...

Association of Inherited Mutations in DNA Repair Genes with Localized Prostate Cancer – Kara Maxwell

Details
Kara Maxwell and Alicia Morgans discuss DNA repair defect alterations in patients with localized prostate cancer. Dr. Maxwell highlights DNA repair in conjunction with prostate cancer, as well as the Penn Medicine BioBank. The conversation concludes with a discussion on the future of prostate cancer genomics. Biographies: Kara N. Maxwell, MD, Ph.D., Assistant Professor of Medicine and Genetics, Un...

NCCN Guidelines 2022 - Prostate Cancer on Comparison of Treatment Options for Localized Disease + Local Therapies + Disease Monitoring - Zachary Klaassen and Chris Wallis

Details
This UroToday journal presented by Zachary Klaassen and Christopher J.D. Wallis discusses Version 1 2022 Prostate Cancer guidelines discussing the comparison of treatment options for localized disease followed by a discussion on local therapies and finally disease monitoring. Biographies: Christopher J.D. Wallis, MD, Ph.D., Assistant Professor in the Division of Urology at the University of Toront...

Treatment-Related Regret Among Men With Localized Prostate Cancer Journal Club - Christopher Wallis & Zachary Klaassen

Details
In this UroToday Journal Club video, Drs Christopher Wallis and Zachary Klaassen highlight a JAMA Oncology publication "Association of Treatment Modality, Functional Outcomes, and Baseline Characteristics With Treatment-Related Regret Among Men With Localized Prostate Cancer". This work aimed to assess the association between treatment approach, functional outcomes, patient expectations, and treat...

High Risk Prostate Cancer and Genomics - Paul Nguyen & Alan Pollack

Details
Paul Nguyen and Alan Pollack join Alicia Morgans in a discussion on risk prognostication in high-risk prostate cancer. Dr. Nguyen discusses the role of genomics to risk-stratify high-risk prostate cancer patients and the role of Decipher at the time of biopsy. He reviews data from an oral presentation he delivered at the 2021 American Society for Radiation Oncology (ASTRO) annual meeting titled: V...

NCCN Prostate Cancer Clinical Practice Guidelines on Risk Stratification for Clinically Localized Prostate Cancer – Christopher Wallis & Zachary Klaassen

Details
In this UroToday Journal Club presentation Christopher Wallis and Zachary Klaassen, continue their in-depth review of the NCCN clinical practice guidelines in prostate cancer focusing on risk stratification for clinically localized disease. They focus on risk stratification for patients with prostate cancer. Dr. Christopher Wallis discusses the use of nomograms and the use of Tumor Multigene Molec...

Improving the Quality of Care for Men in Michigan With Prostate Cancer, the MUSIC Collaborative, a Focus on the G-MINOR and G-MAJOR Trials – Todd Morgan

Details
In this conversation, Todd Morgan joins Mathew Cooperberg highlighting the success and current initiatives of the Michigan Urological Surgery Improvement Collaborative (MUSIC), program. MUSIC is an initiative started in 2012 by Drs. David Miller and Jim Montie in an effort to continuously improve the quality of care for men in Michigan with prostate cancer, MUSIC developed a systematic approach, o...

Personalized Hormone Therapy with Post-Operative Radiation Therapy and Validation of the Decipher Genomic Classifier in SAKK 09/10 Trial - Dan Spratt and Alan Dal Pra

Details
In this UroToday presentation Daniel Spratt, MD, and Alan Dal Pra, MD, share results from recent clinical trials that highlight the timing and patient selection for the personalization of hormone therapy with postoperative radiation therapy and the clinical implications for Decipher. Biographies: Daniel Spratt, MD, Vincent K. Smith Chair in Radiation Oncology, University Hospitals Seidman Cancer C...

When to Add ADT to Early or Late Salvage Radiation - Dan Spratt

Details
Daniel Spratt, MD, reviews the data from two trials that demonstrate the selection of patients for the addition of hormone therapy (ADT) to post-prostatectomy radiation therapy. Dr. Spratt discusses two phase three trials that have evaluated hormonal therapy in the postoperative RP setting with a rising PSA. The RTOG 9601 trial and the GETUG-AFU 16 trial are distinct from each other where the RTOG...
email news signup